posted on 2001-08-01, 00:00authored byT Diamond, P Sambrook, M Williamson, L Flicker, Caryl NowsonCaryl Nowson, M Fiatarone-Singh, S Lord, L Ferris, S O`Neil, A MacLennan
BACKGROUND: Osteoporosis is associated with significant morbidity and mortality in men. Published randomised controlled trials assessing the benefits of therapy in men with osteoporosis are limited, but those available need to be used to develop management guidelines.
OBJECTIVE: To present evidence based guidelines for the treatment of osteoporosis in men.
DISCUSSION: It is estimated that 30-60% of men presenting with spinal fractures have another illness contributing to their bone disease. Therefore assessment and treatment of coexisting medical conditions is a vital part of management of osteoporosis. While primary prevention of fractures remains crucial, treatment to ensure further fractures do not occur is equally important. Alendronate is the treatment of choice for men with osteoporosis and fractures, with cyclical etidronate an appropriate alternative and testosterone replacement therapy is indicated in hypogonadal men presenting with osteoporosis.
History
Journal
Australian family physician
Volume
30
Pagination
787 - 791
Location
Sydney, N.S.W., Australia
Open access
Yes
ISSN
0300-8495
Language
eng
Notes
Copyright to Australian Family Physician. Reproduced with permission. Permission to reproduce must be sought from the publisher, The Royal Australian College of General Practitioners.